Marilyn J Manco-Johnson

List of Publications by Year
in descending order

103	5,108	186265	88630
papers	citations	28 h-index	70 g-index

109	109	109	3299
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 129.	7.4	37
2	The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12690.	2.3	37
3	Novel characteristics of soluble fibrin: hypercoagulability and acceleration of blood sedimentation rate mediated by its generation of erythrocyte-linked fibers. Cell and Tissue Research, 2022, 387, 479-491.	2.9	2
4	Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophiliaâ€"Hematology Utilization Group Study Part VII (HUGS VII). Journal of Blood Medicine, 2022, Volume 13, 229-241.	1.7	2
5	Factor VIIa treatment increases circulating extracellular vesicles in hemophilia patients: Implications for the therapeutic hemostatic effect of FVIIa. Journal of Thrombosis and Haemostasis, 2022, 20, 1928-1933.	3.8	6
6	Biomarkers of bone disease in persons with haemophilia. Haemophilia, 2021, 27, 149-155.	2.1	8
7	Prophylaxis for children with moderate hemophilia: Use of a guideline to increase early initiation. Pediatric Blood and Cancer, 2021, 68, e28577.	1.5	0
8	Current challenges for men and women with mildâ€toâ€moderate haemophilia. Haemophilia, 2021, 27, 5-7.	2.1	2
9	Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate). Haemophilia, 2021, 27, 87-95.	2.1	23
10	Validation of Outcome Instruments for Pediatric Postthrombotic Syndrome: Introducing the Peds-VEINES-QOL, a New Health-Related Quality of Life Instrument. Thrombosis and Haemostasis, 2021, 121, 1367-1375.	3.4	5
11	Improvements in Communication and Coordination of Care in a Hemophilia Treatment Center. Acta Haematologica, 2021, 144, 672-677.	1.4	0
12	Antithrombin deficiency: A pediatric disorder. Thrombosis Research, 2021, 202, 45-51.	1.7	11
13	Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12531.	2.3	18
14	Early Findings on the Use of Motion Capture during Simulated Sports Activities to Better Understand Hemophilic Arthropathy. Blood, 2021, 138, 3203-3203.	1.4	1
15	Association of Hemophilia a Inhibitor Status and Patient-Reported Outcomes with Work Productivity and Health-Related Quality of Life. Blood, 2021, 138, 4069-4069.	1.4	0
16	Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderateâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 285-294.	3.8	6
17	Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. Haemophilia, 2020, 26, 1072-1080.	2.1	14
18	Disseminated Intravascular Coagulation Is an Independent Predictor of Adverse Outcomes in Children in the Emergency Department with Suspected Sepsis. Journal of Pediatrics, 2020, 225, 198-206.e2.	1.8	6

#	Article	IF	Citations
19	Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Advances, 2020, 4, 2451-2459.	5.2	67
20	Application of Thrombomodulin-Thrombin Generation to Diverse Abnormalities of the Protein C System. Blood, 2020, 136, 31-32.	1.4	1
21	Impact of Hemophilia a Inhibitor on Joint Health and Health-Related Quality of Life from the Hemophilia Utilization Group Studies Part VIII in the U.S. Blood, 2020, 136, 8-9.	1.4	0
22	Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia, 2019, 25, 867-875.	2.1	8
23	Community counts: Evolution of a national surveillance system for bleeding disorders. American Journal of Hematology, 2018, 93, E137-E140.	4.1	15
24	Variants in chondroitin sulfate metabolism genes in thrombotic storm. Thrombosis Research, 2018, 161, 43-51.	1.7	5
25	A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Advances, 2018, 2, 1325-1333.	5.2	43
26	Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood, 2017, 129, 2368-2374.	1.4	121
27	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B â€“ the impact of prophylactic treatment. British Journal of Haematology, 2017, 179, 298-307.	2.5	56
28	Pediatric Thrombolysis: A Practical Approach. Frontiers in Pediatrics, 2017, 5, 260.	1.9	47
29	Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency. Thrombosis and Haemostasis, 2016, 116, 58-68.	3.4	19
30	Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. Thrombosis and Haemostasis, 2016, 115, 913-920.	3.4	27
31	Inter-Rater Reliability of the CASCADE Criteria. Stroke, 2016, 47, 2443-2449.	2.0	30
32	Breakthrough Bleeding in Hemophilia a Patients on Prophylaxis. Blood, 2016, 128, 2581-2581.	1.4	5
33	Outcomes of Severe Hemophilia a Patients on Continuous Prophylaxis Relative to Inhibitor Status in the Community Counts Registry. Blood, 2016, 128, 1405-1405.	1.4	0
34	Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism. Thrombosis Research, 2015, 136, 535-541.	1.7	30
35	Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism. Thrombosis Research, 2015, 135, 659-665.	1.7	16
36	Inflammatory predictors of neurologic disability after preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology, 2015, 212, 212.e1-212.e9.	1.3	56

#	Article	IF	Citations
37	Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855). Blood, 2015, 126, 2300-2300.	1.4	2
38	Use of Institutional Clinical Care Guidelines to Determine HA-VTE Risk Level for Consideration of Thromboprophylaxis in Hospitalized Children. Blood, 2015, 126, 3276-3276.	1.4	0
39	Differences in Thrombotic Risk Factors in Black and White Women with Adverse Pregnancy Outcome. Thrombosis Research, 2014, 133, 108-111.	1.7	17
40	FVIII/VWF ratio is not a reliable predictor of VWD in children. Pediatric Blood and Cancer, 2014, 61, 936-939.	1.5	5
41	Thromboelastographic phenotypes of fibrinogen and its variants: Clinical and non-clinical implications. Thrombosis Research, 2014, 133, 1115-1123.	1.7	23
42	Effect on Joint Health of Routine Prophylaxis with Bayerâ€™s Sucrose-Formulated Recombinant Factor VIII (rFVIII-FS) in Adolescents and Adults Previously Treated on Demand: MRI Analyses from the 3-Year Spinart Study. Blood, 2014, 124, 2854-2854.	1.4	3
43	Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial. Blood, 2014, 124, 4271-4271.	1.4	0
44	Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. New England Journal of Medicine, 2013, 369, 2313-2323.	27.0	307
45	The Effect of Factor VIII Deficiencies and Replacement and Bypass Therapies on Thrombus Formation under Venous Flow Conditions in Microfluidic and Computational Models. PLoS ONE, 2013, 8, e78732.	2.5	50
46	Natural History Of Inhibitor Recurrence Following Successful Immune Tolerance Induction. Blood, 2013, 122, 1106-1106.	1.4	2
47	Biomarkers Of Bone Disease In Subjects With Hemophilia. Blood, 2013, 122, 1113-1113.	1.4	5
48	Prompt Immune Tolerance Induction at Inhibitor Diagnosis Regardless of Titer May Increase Overall Success in Hemophilia A With Inhibitors: Experience of Two US Centers. Blood, 2013, 122, 575-575.	1.4	1
49	Antiphospholipid Antibodies Increase Von Willebrand Factor-Platelet String Formation From Human Endothelial Cells Under Physiologic Flow Conditions. Blood, 2013, 122, 2305-2305.	1.4	6
50	Registry Of Patients Treated With Protein C Concentrate (Human) In The United States and Europe: Interim Results. Blood, 2013, 122, 1146-1146.	1.4	0
51	Clinical causes and treatment of the thrombotic storm. Expert Review of Hematology, 2012, 5, 653-659.	2.2	29
52	Treatment, Survival, and Thromboembolic Outcomes of Thrombotic Storm in Children. Journal of Pediatrics, 2012, 161, 682-688.e1.	1.8	20
53	Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score. Arthritis Care and Research, 2011, 63, 223-230.	3.4	224
54	A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells,. Blood, 2011, 118, 3309-3309.	1.4	1

#	Article	IF	Citations
55	Continued Transmission of Parvovirus B19 in Plasma-Derived Factor Concentrates After the Implementation of B19 Nucleic Acid Plasma Minipool Screening,. Blood, 2011, 118, 3378-3378.	1.4	0
56	A Novel Missense Mutation in FGG (c.944C>A) Encodes for An Amino Acid Change (p.Ala315Asp) in the Gamma Chain of Fibrinogen Causing Hypofibrinogenemia and a Thrombotic Phenotype. Blood, 2011, 118, 856-856.	1.4	0
57	Findings of Feasibility Assessment From Multicenter Clinical Trials of Antithrombotic Therapy in Pediatric Venous Thromboembolism. Blood, 2011, 118, 4323-4323.	1.4	0
58	Identification of Patients At High Risk for Recurrent Venous Thromboembolism by Whole Blood Gene Expression Analysis. Blood, 2011, 118, 2305-2305.	1.4	8
59	Whole-Exome Sequencing Identifies Novel Risk Variant for Thrombotic Storm. Blood, 2011, 118, 1229-1229.	1.4	0
60	Consequences of Switching From Prophylactic Treatment to On-Demand Treatment in Late Teens and Early Adults with Severe Hemophilia A. the TEEN/TWEN Study. Blood, 2011, 118, 2288-2288.	1.4	0
61	High Prevalence of Thrombophilic Traits in Children with Family History of Thromboembolism. Journal of Pediatrics, 2010, 157, 485-489.	1.8	27
62	Validation of Upper Extremity Post-Thrombotic Syndrome Outcome Measurement in Children. Journal of Pediatrics, 2010, 157, 852-855.	1.8	26
63	Advances in the Care and Treatment of Children with Hemophilia. Advances in Pediatrics, 2010, 57, 287-294.	1.4	10
64	Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children. Circulation, 2010, 121, 1838-1847.	1.6	383
65	Intra-Abdominal Venous Thrombosis: Characteristics of Pediatric and Adult Patients. Blood, 2010, 116, 4219-4219.	1.4	0
66	Athletic Participation in Severe Hemophilia: Bleeding and Joint Outcomes in Children on Prophylaxis. Pediatrics, 2009, 124, 1267-1272.	2.1	68
67	Post-Thrombotic Syndrome (PTS) in Children: A Systematic Review of Prevalence, Validity of Outcome Measures, and Prognostic Factors.. Blood, 2009, 114, 2978-2978.	1.4	1
68	Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. Blood, 2009, 114, 3993-3993.	1.4	0
69	The Kids-DOTT Trial: Novel Aspects of the â€˜Parallel Cohort RCTâ€˜ Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism.. Blood, 2009, 114, 4169-4169.	1.4	4
70	Findings of Thrombophilia Evaluation and Impact On Management in Asymptomatic Children with a Proximate Family History of Early Thromboembolism: An Institutional-Based Prospective Inceptional Cohort Study.. Blood, 2009, 114, 1289-1289.	1.4	15
71	Afibrinogenemia: a Disorder of Paradoxical Bleeding and Clotting.. Blood, 2009, 114, 3477-3477.	1.4	0
72	Racial Differences in Thrombotic Risk Factors Associated with Adverse Pregnancy Outcome Among Women Obtaining Care in US Thrombosis and Hemostasis Centers.. Blood, 2009, 114, 2982-2982.	1.4	0

#	Article	IF	Citations
73	The CDC Hemostasis and Thrombosis Centers (HTC) Pilot Sites: Data From the Pediatric Registry.. Blood, 2009, 114, 2990-2990.	1.4	0
74	Assessment of Global Hypercoagulability and Fibrinolytic Potential in Pediatric VTE: Findings From A Single-Institutional Prospective Inceptional Cohort Study.. Blood, 2009, 114, 2988-2988.	1.4	0
75	Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study.. Blood, 2009, 114, 3184-3184.	1.4	0
76	When the cause of clotting is not in the bloodâ€"It may be the vessel!. Pediatric Blood and Cancer, 2008, 51, 161-162.	1.5	0
77	A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood, 2007, 110, 45-53.	1.4	138
78	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine, 2007, 357, 535-544.	27.0	1,681
79	Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood, 2006, 108, 3344-3351.	1.4	180
80	A new global assay of coagulation and fibrinolysis. Thrombosis Research, 2005, 116, 345-356.	1.7	76
81	Elevated Plasma Factor VIII and D-Dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children. New England Journal of Medicine, 2004, 351, 1081-1088.	27.0	232
82	Activated Protein C Concentrate Reverses Purpura Fulminans in Severe Genetic Protein C Deficiency. Journal of Pediatric Hematology/Oncology, 2004, 26, 25-27.	0.6	26
83	Evaluation of Physiologic and Pathologic Alterations of Coagulation and Fibrinolysis Using a New Global Assay.. Blood, 2004, 104, 2985-2985.	1.4	1
84	A new euglobulin clot lysis assay for global fibrinolysis. Thrombosis Research, 2003, 112, 329-337.	1.7	103
85	Update on treatment regimens: Prophylaxis versus on-demand therapy. Seminars in Hematology, 2003, 40, 3-9.	3.4	22
86	Development of Coagulation Regulatory Proteins in the Fetal and Neonatal Lamb. Pediatric Research, 2002, 52, 580-588.	2.3	16
87	32P Radiosynoviorthesis in Children With Hemophilia. Journal of Pediatric Hematology/Oncology, 2002, 24, 534-539.	0.6	64
88	Laboratory Testing for Thrombophilia in Pediatric Patients. Thrombosis and Haemostasis, 2002, 88, 155-156.	3.4	122
89	The prothrombin Denver patient has two different prothrombin point mutations resulting in Gluâ€300â†'Lys and Gluâ€309â†'Lys substitutions. British Journal of Haematology, 2000, 108, 182-187.	2.5	27
90	Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. Translational Research, 2000, 136, 74-79.	2.3	26

#	Article	IF	Citations
91	The factor V Leiden mutation in children with cancer and thrombosis. British Journal of Haematology, 1997, 96, 484-489.	2.5	51
92	Disorders of Hemostasis in Childhood: Risk Factors for Venous Thromboembolism. Thrombosis and Haemostasis, 1997, 78, 710-714.	3.4	47
93	Correlation between the Functional Assay for Activated Protein C Resistance and Factor V Leiden in the Neonate. Pediatric Research, 1997, 42, 776-778.	2.3	7
94	Lupus anticoagulant in children with thrombosis. American Journal of Hematology, 1995, 48, 240-243.	4.1	72
95	Identification of a Unique Form of Protein C in the Ovine Fetus: Developmentally Linked Transition to the Adult Form. Pediatric Research, 1995, 37, 365-372.	2.3	21
96	Effect of Hyperinsulinemia on the Development of Blood Coagulation in the Lamb Fetus. Pediatric Research, 1995, 38, 169-172.	2.3	3
97	Hyperglycemia-Induced Hyperinsulinemia Decreases Maternal and Fetal Plasma Protein C Concentration during Ovine Gestation. Pediatric Research, 1994, 36, 293-299.	2.3	8
98	Results of secondary prophylaxis in children with severe hemophilia. American Journal of Hematology, 1994, 47, 113-117.	4.1	156
99	Protein C concentrate prevents peripartum thrombosis. American Journal of Hematology, 1992, 40, 69-70.	4.1	29
100	Heparin cofactor II in adults and infants with thrombosis and DIC. American Journal of Hematology, 1989, 31, 109-113.	4.1	17
101	Pulmonary vascular extraction of circulating norepinephrine in infants with bronchopulmonary dysplasia. Pediatric Pulmonology, 1987, 3, 386-391.	2.0	22
102	Severe thrombophilias. , 0, , 166-179.		0
103	New anticoagulants in children: A review of recent studies and a look to the future. , 0, , 200-206.		0